Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development […]
Noodles & Company Names Scott Davis as Chief Concept Officer
As Former Chief Concept Officer at Panera Bread, Davis led culinary development, category management, restaurant design, and sustainability efforts. At […]
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June […]
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
Venlo, the Netherlands, June 12, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2023 […]
QIAGEN veröffentlicht Nachhaltigkeitsbericht 2023 und hebt Fortschritte bei ESG-Zielen sowie Engagement für nachhaltiges Wachstum hervor
VENLO, Niederlande, June 12, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute seinen Nachhaltigkeitsbericht 2023 veröffentlicht, […]
Array CEO Kevin Hostetler Testifies Before Congress on the Solar Manufacturing Boom from the Inflation Reduction Act
ALBUQUERQUE, N.M., June 12, 2024 (GLOBE NEWSWIRE) — Today, Kevin G. Hostetler, chief executive officer of Array Technologies (NASDAQ: ARRY), […]
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused […]
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization […]
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in […]
Catcha Investment Corp Shareholders Approve Previously Announced Business Combination with Crown LNG Holdings AS
Catcha Shareholders Approved the Previously Announced Business Combination at the Extraordinary General Meeting held June 12, 2024 Crown and Catcha […]
